What is HC Wainwright’s Estimate for UBX FY2026 Earnings?

Unity Biotechnology, Inc. (NASDAQ:UBX) – HC Wainwright lowered their FY2026 earnings per share estimates for Unity Biotechnology in a research report issued on Monday, March 24th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.65) for the year, down from their prior estimate of ($0.42). HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2027 earnings at ($0.09) EPS, FY2028 earnings at $0.25 EPS and FY2029 earnings at $0.40 EPS.

Separately, Chardan Capital lowered their price objective on Unity Biotechnology from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday.

Unity Biotechnology Stock Down 1.7 %

Shares of UBX opened at $1.18 on Thursday. The business’s fifty day moving average is $1.88 and its 200 day moving average is $1.51. Unity Biotechnology has a 12-month low of $0.94 and a 12-month high of $3.10. The stock has a market cap of $19.90 million, a P/E ratio of -0.90 and a beta of 1.02.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Unity Biotechnology stock. Bridgeway Capital Management LLC increased its stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 50,000 shares of the company’s stock after buying an additional 25,000 shares during the period. Bridgeway Capital Management LLC owned about 0.30% of Unity Biotechnology worth $49,000 as of its most recent SEC filing. 29.49% of the stock is currently owned by hedge funds and other institutional investors.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.